Flagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

/PRNewswire/ -- 旗舰先锋公司（Flagship Pioneering），这家生物平台创新公司今日宣布，其内部药物发现与开发部门先锋医药（Pioneering Medicines）已与辉瑞（Pfizer）达成协议，共同发现可能引领下一代自身免疫疾病治疗药物开发的化合物。

The collaboration will engage Charles River to utilize Logica®, a unique platform offering from Valo Health, a Flagship-founded company, to identify advanceable small molecule leads. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading drug discovery expertise.

此次合作将使Charles River利用Flagship 旗下公司 Valo Health 提供的独特平台Logica ®来识别可推进的小分子线索。Logica 利用 Valo Health 的人工智能驱动型 Opal 计算平台和Charles River领先的药物发现专业知识，将生物学见解转化为优化的临床前资产。

"Autoimmune diseases impose a substantial health burden on patients, and ongoing unmet need in the management of these conditions is driving a strong demand for more effective, safer and more personalized treatment options," said Paul Biondi, President, Pioneering Medicines, and Managing Partner, Flagship Pioneering. "Through the power of our unique partnership model with Pfizer, we will leverage Logica to help address this gap with a promising novel approach to identifying disease-modifying candidate molecules that could positively impact the current treatment landscape for these complex and diverse conditions."

Pioneering Medicines 总裁兼 Flagship Pioneering 执行合伙人Paul Biondi表示：“自身免疫性疾病给患者带来了巨大的健康负担，而这些疾病的管理中一直未得到满足的需求推动了对更有效、更安全、更个性化治疗方案的强烈需求。 通过我们与辉瑞独特的合作模式，我们将利用 Logica 来帮助弥补这一差距，采用一种有前途的新方法来识别可以改变疾病的候选分子，这些分子可能会对这些复杂多样疾病的当前治疗前景产生积极影响。”

This agreement represents the sixth collaboration signed under the broader strategic partnership between Flagship Pioneering and Pfizer to create a new pipeline of innovative assets, following programs announced with Flagship companies ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines.

该协议是 Flagship Pioneering 与辉瑞在更广泛的战略合作伙伴关系下签署的第六项合作， 旨在创建新的创新资产管线，此前双方已宣布与 Flagship 公司ProFound Therapeutics、Quotient Therapeutics、Montai Therapeutics和Ampersand Biomedicines开展项目。

"We are excited to bring the power of the Logica platform – powered by Valo and Charles River – to discover potential investigational therapies for patients suffering from autoimmune diseases," said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. "Logica's proprietary AI small molecule drug discovery platform is revolutionizing the drug discovery process, and we look forward to working with the joint team at Pioneering Medicines and Pfizer to accelerate understanding of the molecular pathways involved in these diseases to develop more targeted and effective therapies for patients."

Charles River高级副总裁兼首席科学官Julie Frearson博士表示： “我们很高兴能够利用由Valo 和 Charles River支持的 Logica 平台的力量，为患有自身免疫性疾病的患者发现潜在的试验性疗法。Logica专有的 AI 小分子药物发现平台正在彻底改变药物发现过程，我们期待与 Pioneering Medicines 和辉瑞的联合团队合作，加速了解这些疾病所涉及的分子途径，为患者开发更有针对性和更有效的疗法。”